Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction

Myocardial Infarction, Acute Clinical Trial

Official title:

Expression of microRNA-133a and microRNA-208b in Acute Myocardial Infarction Egyptian Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05692752
• Other study ID #: UCCM/2022/EGT/01
• Status: Completed
• Start date: December 28, 2022
• Est. completion date: January 14, 2023

Study information

• Verified date: January 2023
• Source: Islamia University of Bahawalpur
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Cardiac-enriched micro-RNAs (miRNAs), micro RNA 208b and 133a(MiR-208b, MiR-133a)) corresponds to the health and disorders of the cardiovascular system. An intron of the cardiac myosin heavy chain gene MYH7 encodes miR-208b. It is found on chromosome 14 in humans. Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cardiac troponine (cTnl) and Creatine kinase-MB (CK-MB).

Description:

The 98% of human genes are non-coding RNA, which is further divided into long non-coding RNA (lncRNA, > 200 bp) and short non-coding RNA (200 bp, including microRNA (miRNA) and circular RNA). More than 2000 human miRNAs have been discovered, and it seems that they regulate around 60% of human genes.Through a number of pathways, miRNAs control the development, re-modelling, and regeneration of the heart as well as endothelial function, vasculo-genesis, and neoangiogenesis. 30% of the genes in the human genome are regulated by about 1000 miRNAs. Endogenous miRNAs are 19-22 nucleotide single-stranded RNA molecules that frequently target the 3' untranslated regions (3'-UTR) of mRNAs to regulate gene expression at the post-transcriptional level in physiological processes, disease development, and conditions like cancer, autoimmune and inflammatory diseases, neuro-degenerative diseases, and cardiovascular diseases. Cardiac-enriched miRNAs, MiR-208 in health and disorders of the cardiovascular system are investigated.

Identify new diagnostic biomarkers based on miRNAs, researchers examine the expression of miR-133a and 208b at various time points (04 hours, 08 hours, 12 hours, 24 hours, 48 hours) following the development of the infarct and compared it to the traditional myocardial infarction biomarkers cTnl and CK-MB.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: January 14, 2023
• Est. primary completion date: January 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients diagnosed with ST-Elevated Myocardial Infarction will be identified at the Coronary Care Unit at Ain-shams University hospital

2. Acute episode of Myocardial Infarction

3. With No history of previous Myocardial Infarction Treatment

Exclusion Criteria:

1. Patients not diagnosed with ST-Elevated Myocardial Infarction and healthy at the Coronary Care Unit at Ain-shams 2. University hospital

2. Previously Known patients of Myocardial infacrtion

3. Previous medication

Related Conditions & MeSH terms

• Infarction
• Myocardial Infarction
• Myocardial Infarction, Acute

Intervention

Other:
• No intervention
Expression of miR-133a &208b at 4, 8, 12, 24 and 48 hours from the first appearance of myocardial infarction (MI) symptoms

Locations

Country	Name	City	State
Egypt	Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance Al Tagamoa Al Khames	Cairo

Sponsors (2)

Lead Sponsor	Collaborator
Islamia University of Bahawalpur	German University in Cairo

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression of miR-133a	Expression during episodes of myocardial infarction	04 hours from the onset of the infarct
Primary	Expression of miR-133a	Expression during episodes of myocardial infarction	08 hours from the onset of the infarct
Primary	Expression of miR-133a	Expression during episodes of myocardial infarction	12 hours from the onset of the infarct
Primary	Expression of miR-133a	Expression during episodes of myocardial infarction	24 hours from the onset of the infarct
Primary	Expression of miR-133a	Expression during episodes of myocardial infarction	48 hours from the onset of the infarct
Primary	Expression of miR-208b	Expression during episodes of myocardial infarction	04 hours from the onset of the infarct
Primary	Expression of miR-208b	Expression during episodes of myocardial infarction	08 hours from the onset of the infarct
Primary	Expression of miR-208b	Expression during episodes of myocardial infarction	12 hours from the onset of the infarct
Primary	Expression of miR-208b	Expression during episodes of myocardial infarction	24 hours from the onset of the infarct
Primary	Expression of miR-208b	Expression during episodes of myocardial infarction	48 hours from the onset of the infarct